HelioLiver LDT is a simple blood test that helps detect hepatocellular carcinoma (HCC) in high-risk patients, including people with cirrhosis or chronic hepatitis B. In the CLiMB trial, HelioLiver detected Stage I liver cancer four times more often than ultrasound.
HelioLiver LDT is a simple blood test for early liver cancer detection. By combining cell-free DNA methylation testing with protein tumour markers and clinical information, it helps identify HCC earlier in high-risk patients. The test is designed to fit into routine surveillance and provide a simpler path to earlier answers.
Reads the DNA methylation signals of cancer circulating in the blood.
Adds a second, independent layer of signal alongside the methylation data.
Brings both signals together for a clear result in high-risk patients.
AI brings every signal together into a single Normal or Abnormal report on the likelihood of HCC.
Normal · AbnormalHelioLiver LDT combines cell-free DNA methylation testing with protein tumour markers to detect liver cancer earlier than ultrasound, the current standard of care, especially the small, early-stage lesions that are hardest to catch.
HelioLiver is backed by one of the largest prospective liver cancer detection trials in the United States and is now available to order through Quest Diagnostics, putting earlier detection within reach of physicians nationwide.
Studied across 42 US clinical sites in the pivotal CLiMB trial, with MRI as the reference standard.
Now available to order through one of the largest diagnostic networks in the United States.
Peer-reviewed and published in the Journal of Hepatology, building on nearly a decade of research.
HelioLiver LDT supports liver cancer screening and HCC surveillance in high-risk patients, using a simple blood draw that fits existing office workflows. Ordering support is available for provider offices.
Order HelioLiver
If you have cirrhosis or another liver cancer risk factor, ask your doctor about HelioLiver LDT. Risk factors include chronic hepatitis B, hepatitis C, alcohol-related liver disease, and fatty liver disease.
Learn About HelioLiverLiver cancer is often diagnosed late, when treatment options are more limited. Finding HCC earlier can expand the range of therapies and improve the chance of better outcomes.
Each provider is set up with an ordering process that fits their office, through TRF or EMR.
The HelioLiver Collection Kit includes everything needed to collect and prepare the sample.
A prepaid return shipping label is included in every kit.
Average turnaround is 10–14 days.
A clear Normal or Abnormal result indicating the likelihood of HCC.
HelioLiver's landmark CLiMB study is now peer-reviewed and published.
Read MoreA commercial partnership supporting liver cancer detection expansion.
Read MoreA conversation on the future of liver cancer surveillance.
Watch the InterviewHelioLiver LDT gives physicians and patients a simpler way to catch liver cancer when it is most treatable.